Search / Trial NCT00001733

Screening for Studies on Retinovascular Diseases

Launched by NATIONAL EYE INSTITUTE (NEI) · Nov 3, 1999

Trial Information

Current as of October 18, 2024

Completed

Keywords

Diabetic Retinopathy Age Related Macular Degeneration Neovascularization Macular Degeneration Retinal Disease Diabetes

Description

This protocol is designed for the screening of patients with presumed retinovascular diseases. It serves as a first step for individuals who may be eligible and wish to participate in National Eye Institute clinical research studies of retinovascular diseases. Each individual will be thoroughly evaluated during the screening process to determine if they are suitable candidates for inclusion in any of the National Eye Institute ongoing studies. The screening evaluation will include past and current medical histories and an appropriate physical examination, namely a comprehensive eye exam. O...

Gender

ALL

Eligibility criteria

  • * INCLUSION/EXCLUSION CRITERIA
  • Inclusion and exclusion criteria vary with the particular protocol for which a patient is being screened.
  • In addition to those diagnoses currently under study, subjects with unknown conditions that require the establishment of a diagnosis may be eligible for inclusion in this study.
  • All studies of retinovascular diseases require the subject to have minimum age of 18 years in both men and women.

About National Eye Institute (Nei)

The National Eye Institute (NEI), part of the U.S. National Institutes of Health (NIH), is dedicated to conducting and supporting innovative research to understand, prevent, and treat eye diseases and vision disorders. As a leading sponsor of clinical trials, NEI aims to advance knowledge in ocular health through rigorous scientific inquiry and collaboration with researchers, healthcare professionals, and institutions. By fostering the development of new therapies and technologies, NEI plays a pivotal role in enhancing the quality of life for individuals affected by visual impairments and eye conditions.

Locations

Bethesda, Maryland, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0